We are excited that PhenoPath can serve as a resource to the pathology and oncology communities in offering the various companion and complementary PD-L1 IHC assays to permit optimal patient treatment.
Seattle, WA (PRWEB) December 11, 2015
“This new class of drugs, targeting the PD-L1/PD1 immune checkpoint, promises to revolutionize treatment of a number of malignancies, including non small cell lung carcinoma, melanoma, renal cell carcinoma, and others. We are excited that PhenoPath can serve as a resource to the pathology and oncology communities in offering the various companion and complementary PD-L1 IHC assays to permit optimal patient treatment.”
Allen M. Gown, MD
Founder & Medical Director
Physicians can order both the Dako PD-L1 IHC 22C3 pharmDx and Dako PD-L1 IHC 28-8 pharmDx immunohistochemistry tests directly from PhenoPath, in addition to a generic PD-L1 expression immunohistochemistry test employing Cell Signaling Technology’s EIL3N antibody clone. PhenoPath is one of the first laboratories in the nation to have all these assays validated and available.
PhenoPath is a national and internationally-recognized physician-owned and directed specialty pathology consultative practice and reference laboratory providing diagnostic and BioPharma pathology services in the U.S., Canada and around the world. In addition to a broad range of consultative expertise in solid tumor and hematolymphoid tumors, PhenoPath is on the forefront of state-of-the-art technologies, including immunohistochemistry, flow cytometry, fluorescence in situ hybridization and molecular assays as well as chromosome analysis. For more information, contact us at 888-927-4366.
Contacts: Dr. Allen M. Gown, Dr. Regan Fulton